Antiviral therapy of COVID-19
The COVID-19 pandemic required rapid response to the needs of critically ill patients, and one of the solutions was re-purposing of drugs with wide spectrum of antiviral action for treatment of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. The re-purposing characteristi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
2020-01-01
|
| Series: | Scripta Medica |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003131J.pdf |
| _version_ | 1819033231371010048 |
|---|---|
| author | Janković Slobodan M. |
| author_facet | Janković Slobodan M. |
| author_sort | Janković Slobodan M. |
| collection | DOAJ |
| description | The COVID-19 pandemic required rapid response to the needs of critically ill patients, and one of the solutions was re-purposing of drugs with wide spectrum of antiviral action for treatment of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. The re-purposing characteristically started with outof-label use in single or series of cases, to continue after the first promising results with randomised clinical trials. There are several drugs that are currently tested in ongoing clinical trials: antimalarials hydroxychloroquine and chloroquine, HIV protease inhibitors lopinavir/ritonavir, broad spectrum antivirals umifenovir (anti-influenza drug) and favipiravir, antiparasitary drug ivermectin and nucleotide analogue remdesivir. However, up to date only a few trials are completed and published, precluding definitive conclusions about efficacy and safety of these drugs. Until major clinical trials are completed, physicians who decide to use these drugs out-of-label should properly inform their patients of all potential risks and benefits and seek for their consent before administration of the drugs. |
| first_indexed | 2024-12-21T07:14:33Z |
| format | Article |
| id | doaj.art-b911ba7419374679864e02a0a5ed7e75 |
| institution | Directory Open Access Journal |
| issn | 2490-3329 2303-7954 |
| language | English |
| last_indexed | 2024-12-21T07:14:33Z |
| publishDate | 2020-01-01 |
| publisher | Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine |
| record_format | Article |
| series | Scripta Medica |
| spelling | doaj.art-b911ba7419374679864e02a0a5ed7e752022-12-21T19:11:54ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542020-01-015131311332490-33292003131JAntiviral therapy of COVID-19Janković Slobodan M.0https://orcid.org/0000-0002-1519-8828University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology, SerbiaThe COVID-19 pandemic required rapid response to the needs of critically ill patients, and one of the solutions was re-purposing of drugs with wide spectrum of antiviral action for treatment of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. The re-purposing characteristically started with outof-label use in single or series of cases, to continue after the first promising results with randomised clinical trials. There are several drugs that are currently tested in ongoing clinical trials: antimalarials hydroxychloroquine and chloroquine, HIV protease inhibitors lopinavir/ritonavir, broad spectrum antivirals umifenovir (anti-influenza drug) and favipiravir, antiparasitary drug ivermectin and nucleotide analogue remdesivir. However, up to date only a few trials are completed and published, precluding definitive conclusions about efficacy and safety of these drugs. Until major clinical trials are completed, physicians who decide to use these drugs out-of-label should properly inform their patients of all potential risks and benefits and seek for their consent before administration of the drugs.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003131J.pdfcovid-19antiviral agentsdrug repurposingout-of-label useadverse effects |
| spellingShingle | Janković Slobodan M. Antiviral therapy of COVID-19 Scripta Medica covid-19 antiviral agents drug repurposing out-of-label use adverse effects |
| title | Antiviral therapy of COVID-19 |
| title_full | Antiviral therapy of COVID-19 |
| title_fullStr | Antiviral therapy of COVID-19 |
| title_full_unstemmed | Antiviral therapy of COVID-19 |
| title_short | Antiviral therapy of COVID-19 |
| title_sort | antiviral therapy of covid 19 |
| topic | covid-19 antiviral agents drug repurposing out-of-label use adverse effects |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003131J.pdf |
| work_keys_str_mv | AT jankovicslobodanm antiviraltherapyofcovid19 |